Review Article
Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life
Miguel A. Escobar,(1) MD, Cindy Leissinger,(2) MD, and Guy Young,(3) MD
From (1)University of Texas Health Science Center and Gulf States Hemophilia & Thrombophilia Center, Houston, Texas; (2)Louisiana Center for Bleeding and Clotting Disorders New Orleans, Louisiana; (3)Hemostasis & Thrombosis Center, Children’s Hospital Los Angeles, and University of Southern California, Keck School of Medicine, Los Angeles, California
Authors’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2022;13(Suppl 3):7–19 |
https://doi.org/10.6004/jadpro.2022.13.4.8 |
© 2022 Harborside™
ABSTRACT
Hemophilia A is a rare inherited bleeding disorder characterized by a deficiency in factor VIII. The evolution of currently approved prophylaxis therapy in hemophilia A will be reviewed, including the clinical value of prophylaxis, real-world experience with prophylaxis, and patient quality-of-life factors that must be considered when choosing treatment options for these patients.
For access to the full length article, please
sign in.
